Bioingenium

Executive Summary

Bioingenium is a Spanish Contract Development and Manufacturing Organization (CDMO) specializing in recombinant protein expression and bioprocess development. Founded in 2008, the company leverages three core technology platforms—bacterial, mammalian, and yeast (Pichia pastoris) expression—to support clients from proof-of-concept through non-GMP scale-up manufacturing. Serving over 150 companies globally across biopharma, biotech, and cosmetics sectors, Bioingenium has established a reputation for flexible, high-quality services. The company’s expertise in multiple expression systems allows it to cater to a diverse range of protein production needs, positioning it as a reliable partner for early-stage bioprocess development. While Bioingenium operates as a private entity and does not disclose financials, its long-standing presence and broad client base indicate stable operations. The CDMO market is growing, driven by increasing demand for biologics and outsourcing, which could present opportunities for Bioingenium to expand its capacity and service offerings.

Upcoming Catalysts (preview)

• Q4 2026Capacity Expansion for Mammalian and Yeast Platforms60% success
• Q1 2027Strategic Partnership with a Major Biopharma Company30% success
• Q2 2027Adoption of Continuous Manufacturing Technology40% success